Katharina Modelska1, Steven Cummings. 1. Prevention Sciences Group, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. kmodelska@psg.ucsf.edu
Abstract
OBJECTIVE: This systematic review includes all randomized and placebo-controlled trials (RCTs) of treatment for female sexual dysfunction (FSD) in postmenopausal women published since 1990. STUDY DESIGN: Electronic database and manual bibliography searches were conducted to identify all relevant publications. RESULTS: Only six RCTs have been done to assess the effects of different therapies on sexual function in postmenopausal women: one with sildenafil citrate (Viagra), three with hormone replacement therapy, and two with tibolone. CONCLUSIONS: In women with FSD, many treatments that are used in practice are not supported by adequate evidence. Although an improvement of sexual function was reported with tibolone and the combination of estrogen-androgen therapy, it still remains unclear which groups of postmenopausal women with FSD would benefit most from these therapies. The adverse effects of testosterone replacement therapy should be assessed against the effects of placebo in RCTs with larger sample sizes and longer duration.
OBJECTIVE: This systematic review includes all randomized and placebo-controlled trials (RCTs) of treatment for female sexual dysfunction (FSD) in postmenopausal women published since 1990. STUDY DESIGN: Electronic database and manual bibliography searches were conducted to identify all relevant publications. RESULTS: Only six RCTs have been done to assess the effects of different therapies on sexual function in postmenopausal women: one with sildenafil citrate (Viagra), three with hormone replacement therapy, and two with tibolone. CONCLUSIONS: In women with FSD, many treatments that are used in practice are not supported by adequate evidence. Although an improvement of sexual function was reported with tibolone and the combination of estrogen-androgen therapy, it still remains unclear which groups of postmenopausal women with FSD would benefit most from these therapies. The adverse effects of testosterone replacement therapy should be assessed against the effects of placebo in RCTs with larger sample sizes and longer duration.
Authors: Steven R Cummings; Bruce Ettinger; Pierre D Delmas; Peter Kenemans; Victoria Stathopoulos; Pierre Verweij; Mirjam Mol-Arts; Lenus Kloosterboer; Lori Mosca; Claus Christiansen; John Bilezikian; Eduardo Mario Kerzberg; Susan Johnson; Jose Zanchetta; Diederich E Grobbee; Wilfried Seifert; Richard Eastell Journal: N Engl J Med Date: 2008-08-14 Impact factor: 91.245
Authors: Hadi Mostafaei; Sandra Jilch; Greta Lisa Carlin; Keiichiro Mori; Fahad Quhal; Benjamin Pradere; Ekaterina Laukhtina; Victor M Schuettfort; Abdulmajeed Aydh; Reza Sari Motlagh; Claus G Roehrborn; Shahrokh F Shariat; Sakineh Hajebrahimi Journal: Nat Rev Urol Date: 2021-12-23 Impact factor: 14.432